KRAS and lung adenocarcinoma: Interestingly, we can see the opposite effects on lung adenocarcinomas; KRAS mutant lung adenocarcinoma cell lines are more sensitive to N-bisphosphonates (p = 0.136) and to FTis (p = 0.007) than wild-type cells.